Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22317517 | 0.95 | DNM1 (0.54) | DNM1CNR1DRD2DRD4EPHX1 | |
| SCHEMBL21017146 | 0.93 | DNM1 (0.57) | DNM1CNR1DRD2DRD4EPHX1 | |
| SCHEMBL24401517 | 0.86 | DNM1 (0.51) | DNM1CNR1EPHX1GLATHRA | |
| SCHEMBL22317611 | 0.83 | DNM1 (0.49) | DNM1CNR1EPHX1GLATHRA | |
| SCHEMBL21017828 | 0.83 | DNM1 (0.49) | DNM1CNR1EPHX1GLATHRA | |
| SCHEMBL10879405 | 0.82 | DNM1 (0.45) | DNM1CNR1ALDH1A1KDM4E | |
| SCHEMBL24926365 | 0.82 | DNM1 (0.55) | DNM1CNR1EPHX1THRATHRB | |
| SCHEMBL409080 | 0.82 | DNM1 (0.44) | DNM1DRD2DRD4CA1CA2 | |
| SCHEMBL19966857 | 0.80 | CNR1 (0.63) | CNR1DRD2DRD4EPHX1ALDH1A1 | |
| SCHEMBL17447537 | 0.80 | ALDH1A1 (0.48) | DNM1CNR1DRD2DRD4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | DNM1 1315/4885CNR1 461/4885DRD2 2758/4885 |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | DNM1 1315/4885CNR1 461/4885DRD2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.